Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.35 |
| ▸ | EIF4EBP1 | Q13541 | 7/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 3/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16634456 | 0.87 | L3MBTL1 (0.44) | L3MBTL1NTRK1NTRK3NTRK2EIF4EBP1 | |
| SCHEMBL16632415 | 0.85 | L3MBTL1 (0.48) | L3MBTL1NTRK1NTRK3NTRK2EIF4EBP1 | |
| SCHEMBL16632787 | 0.80 | RHEB (0.52) | L3MBTL1EIF4EBP1KMT2AMCL1 | |
| SCHEMBL14871823 | 0.78 | L3MBTL1 (0.52) | L3MBTL1NTRK1NTRK3NTRK2XBP1 | |
| SCHEMBL16632486 | 0.78 | L3MBTL1 (0.53) | L3MBTL1EIF4EBP1XBP1DUTMCL1 | |
| SCHEMBL16632611 | 0.78 | L3MBTL1 (0.48) | L3MBTL1NTRK1NTRK3NTRK2EIF4EBP1 | |
| SCHEMBL16632282 | 0.77 | L3MBTL1 (0.47) | L3MBTL1EIF4EBP1MCL1 | |
| SCHEMBL16632349 | 0.77 | L3MBTL1 (0.36) | L3MBTL1DUTCYP19A1TSHRKMT2A | |
| SCHEMBL16632606 | 0.77 | L3MBTL1 (0.39) | L3MBTL1DUTCYP19A1TSHRKMT2A | |
| SCHEMBL16632698 | 0.76 | L3MBTL1 (0.53) | L3MBTL1EIF4EBP1XBP1DUTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382245-B2 | Compounds and methods for treating HIV infections | YALE UNIVERSITY (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105351-A1 | COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS | POLM, POLRMT, DHFR | L3MBTL1 879/4885CCR1 1121/4885NTRK1 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.